Novel Therapies in Glioblastoma
Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent impro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2012/428565 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467726973632512 |
|---|---|
| author | James Perry Masahiko Okamoto Michael Guiou Katsuyuki Shirai Allison Errett Arnab Chakravarti |
| author_facet | James Perry Masahiko Okamoto Michael Guiou Katsuyuki Shirai Allison Errett Arnab Chakravarti |
| author_sort | James Perry |
| collection | DOAJ |
| description | Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent improved understanding of basic tumor biology, targeted therapies have become cornerstones for cancer treatment. Many pathways (RTKs, PI3K/AKT/mTOR, angiogenesis, etc.) have been identified in GBM as playing major roles in tumorigenesis, treatment resistance, or natural history of disease. Despite the growing understanding of the complex networks regulating GBM tumors, many targeted therapies have fallen short of expectations. In this paper, we will discuss novel therapies and the successes and failures that have occurred. One clear message is that monotherapies yield minor results, likely due to functionally redundant pathways. A better understanding of underlying tumor biology may yield insights into optimal targeting strategies which could improve the overall therapeutic ratio of conventional treatments. |
| format | Article |
| id | doaj-art-e018922533384d9aadbe3d088525a3bd |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-e018922533384d9aadbe3d088525a3bd2025-08-20T03:26:05ZengWileyNeurology Research International2090-18522090-18602012-01-01201210.1155/2012/428565428565Novel Therapies in GlioblastomaJames Perry0Masahiko Okamoto1Michael Guiou2Katsuyuki Shirai3Allison Errett4Arnab Chakravarti5Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USAConventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent improved understanding of basic tumor biology, targeted therapies have become cornerstones for cancer treatment. Many pathways (RTKs, PI3K/AKT/mTOR, angiogenesis, etc.) have been identified in GBM as playing major roles in tumorigenesis, treatment resistance, or natural history of disease. Despite the growing understanding of the complex networks regulating GBM tumors, many targeted therapies have fallen short of expectations. In this paper, we will discuss novel therapies and the successes and failures that have occurred. One clear message is that monotherapies yield minor results, likely due to functionally redundant pathways. A better understanding of underlying tumor biology may yield insights into optimal targeting strategies which could improve the overall therapeutic ratio of conventional treatments.http://dx.doi.org/10.1155/2012/428565 |
| spellingShingle | James Perry Masahiko Okamoto Michael Guiou Katsuyuki Shirai Allison Errett Arnab Chakravarti Novel Therapies in Glioblastoma Neurology Research International |
| title | Novel Therapies in Glioblastoma |
| title_full | Novel Therapies in Glioblastoma |
| title_fullStr | Novel Therapies in Glioblastoma |
| title_full_unstemmed | Novel Therapies in Glioblastoma |
| title_short | Novel Therapies in Glioblastoma |
| title_sort | novel therapies in glioblastoma |
| url | http://dx.doi.org/10.1155/2012/428565 |
| work_keys_str_mv | AT jamesperry noveltherapiesinglioblastoma AT masahikookamoto noveltherapiesinglioblastoma AT michaelguiou noveltherapiesinglioblastoma AT katsuyukishirai noveltherapiesinglioblastoma AT allisonerrett noveltherapiesinglioblastoma AT arnabchakravarti noveltherapiesinglioblastoma |